Molecular Targets in Non-Small Cell Lung Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Ochsner Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1043/TOJ-17-0033PMID 29230123PMCID PMC5718451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cited by this paper
• MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

  2017cited by this paper
• Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  2017cited by this paper
• First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

  2017cited by this paper
• Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

  2016cited by this paper
• A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

  2016cited by this paper
• A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.

  2016cited by this paper
• Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

  2016cited by this paper
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  2015cited by this paper
• Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

  2015influential reference
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

  2014cited by this paper
• Acquired resistance to TKIs in solid tumours: learning from lung cancer

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Chipping away at the lung cancer genome

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• Genetic insight and therapeutic targets in squamous-cell lung cancer

  2012cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• F1000 highlights

  2009cited by this paper
• ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004influential reference
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Cancer statistics

  1989cited by this paper

• A Systems Biology and Artificial Intelligence Approach to Unveil Brigatinib’s Pharmacological Mechanism in Brain Metastases in ALK+ Non-Small Cell Lung Cancer

  2026cites this paper
• 3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth

  2025cites this paper
• Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions Between Tyrosine Kinase Inhibitors and Cardiovascular Drugs

  2025cites this paper
• Integrated machine learning and causal inference reveal CHRDL1 as a diagnostic and functional biomarker in NSCLC

  2025cites this paper
• Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

  2024cites this paper
• Small extracellular vesicles: multi-functional aspects in non-small cell lung carcinoma.

  2024cites this paper
• Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis

  2024cites this paper
• YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer

  2024cites this paper
• Animal models in biomedical research: Relevance of Drosophila melanogaster

  2024cites this paper
• Clinicopathological Features, Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase (ALK) Rearrangement-Based Survival of Patients With Advanced Non-small Cell Lung Cancer in a Tertiary Care Setting

  2024cites this paper
• Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

  2024cites this paper
• JI017 Induces Cell Autophagy and Apoptosis via Elevated Levels of Reactive Oxygen Species in Human Lung Cancer Cells

  2023cites this paper
• Fetal Type Morphologies Suggest the Presence of DICER1 Hotspot Mutations in Non–small Cell Lung Cancer

  2023cites this paper
• Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives

  2023cites this paper
• The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.

  2023cites this paper
• AURKA Identified as Potential Lung Cancer Marker through Comprehensive Bioinformatic Analysis and Experimental Verification.

  2023cites this paper
• Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

  2022cites this paper
• Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.

  2022cites this paper
• Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

  2022cites this paper
• Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer

  2022cites this paper
• Methylation analysis of APC, AXIN2, DACT1, RASSF1A and MGMT gene promoters in non-small cell lung cancer.

  2022cites this paper
• Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective

  2022cites this paper
• STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).

  2022cites this paper
• Long Term Survival of Patient with Late-Stage Non-Small Cell Carcinoma of Lung: A Case Report

  2022cites this paper
• Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies

  2022influential citation
• The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET

  2022cites this paper
• Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET

  2022cites this paper
• ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma

  2021cites this paper
• Synthesis and Biological Evaluation of (S)-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells

  2021cites this paper
• Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

  2021cites this paper
• The treatment of advanced lung adenocarcinoma with activating EGFR mutations

  2021cites this paper
• Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis

  2021cites this paper
• Precision treatment for metastatic non–small cell lung cancer: A conceptual overview

  2021cites this paper
• Role of sex hormones in lung cancer

  2021cites this paper
• Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

  2021cites this paper
• Clinical implication of aquaporin 9 in non-small cell lung cancer patients: its expression and relationship with clinical features and prognosis

  2021cites this paper
• Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

  2021cites this paper
• EPIDEMIOLOGY OF NON-SMALL CELL LUNG CANCER ( NSCLC ) IN SOUTH INDIA-EMPHASIS BETWEEN SMOKERS AND NON-SMOKERS

  2020cites this paper
• The Effect of Metformin in EML4-ALK+ Lung Cancer alone and in Combination with Crizotinib in Cell and Rodent Models.

  2020cites this paper
• Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists

  2020cites this paper
• The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.

  2019cites this paper
• A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.

  2019cites this paper
• miR-21 promotes non-small cell lung cancer cells growth by regulating fatty acid metabolism

  2019cites this paper
• Oligo-recurrence from anaplastic lymphoma kinase-rearranged lung adenocarcinoma.

  2019cites this paper
• Radiation Therapy in Non-small-Cell Lung Cancer

  2019cites this paper
• Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study

  2019cites this paper
• Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib

  2019cites this paper
• MiR-185 inhibits cell proliferation and invasion of non-small cell lung cancer by targeting KLF7.

  2019cites this paper
• Point Reached in Targeted Therapy; Where are we?

  2018cites this paper